Qiangxin Technology International Research Institute

Strong Biotechnologies, also known as Qiangxin Technology, is a global biopharmaceutical company focused on the discovery and development of first-in-class targeted therapies for cancer and serious diseases. The company is a pioneer in targeting cancer stem cells (CSCs) and has developed a robust pipeline of small molecules and gene therapies. Its lead research efforts resulted in the development of napabucasin, a first-in-class STAT3 inhibitor designed to block cancer stemness pathways. Headquartered in Beijing with major research centers in Boston and Tokyo, the institute integrates international scientific expertise to address unmet medical needs in oncology and rare genetic disorders. The company continues to advance innovative treatments through its proprietary technology platforms and global clinical trials.